Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rated Buy in New Coverage at HC Wainwright

HC Wainwright began coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research note released on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $55.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on AGIO. Bank of America boosted their price target on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. Truist Financial dropped their target price on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Finally, Royal Bank Of Canada lifted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Agios Pharmaceuticals Price Performance

AGIO opened at $30.55 on Thursday. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -4.36 and a beta of 0.63. The firm’s fifty day moving average price is $33.62 and its two-hundred day moving average price is $31.70. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, equities analysts anticipate that Agios Pharmaceuticals will post -5.85 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 39,855 shares of company stock worth $1,285,512. 5.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors have recently bought and sold shares of AGIO. BlackRock Inc. purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth about $239,582,000. Assenagon Asset Management S.A. lifted its stake in shares of Agios Pharmaceuticals by 1,714.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after buying an additional 1,782,457 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $47,800,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $24,828,000. Finally, SCS Capital Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $22,743,000.

Trending Headlines about Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios said updated safety data showed no new cases of hepatocellular injury in sickle cell patients treated with mitapivat. The company remains confident in the drug’s benefit-risk profile, is launch-ready, and continues labeling discussions with the FDA. Agios FDA review update
• Positive Sentiment: An analyst view argued that the delay may not invalidate the bullish thesis because mitapivat demonstrated meaningful reductions in transfusion burden, despite mixed efficacy on pain-crisis endpoints. Seeking Alpha upgraded the stock, while HC Wainwright maintained a “buy” rating with a $55 price target. Agios sickle cell analysis
• Neutral Sentiment: Agios was expected to potentially beat estimates in its upcoming quarterly report, but the earnings preview provided no confirmed results or new operating data. Agios earnings preview
• Negative Sentiment: The FDA extended the PDUFA decision date for mitapivat’s sickle cell supplemental application by three months, from November 1, 2026, to February 1, 2027. The extension followed the agency’s request for additional information on whether a Risk Evaluation and Mitigation Strategy (REMS) is needed. The FDA classified Agios’ response as a major amendment, delaying a potential approval and launch timeline. Agios shares fall on FDA review extension
• Negative Sentiment: The REMS review raises concerns about possible safety-related prescribing restrictions and commercialization requirements. In addition, mitapivat did not meet the sickle-cell pain-crisis endpoint, increasing uncertainty around the breadth of its eventual label.
• Negative Sentiment: A recent pre-arranged sale by Chief Medical Officer Sarah Gheuens adds a modest negative sentiment signal, although the transaction was not identified as the primary reason for the selloff. Agios insider sale

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.